SUBSCRIPTION AGREEMENT dated as of September 3, 2020 by and between [NAME OF INVESTOR] and I-MABSubscription Agreement • December 1st, 2020 • I-Mab • Pharmaceutical preparations • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of September 3, 2020, by and between I-Mab, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), and [Name of Investor] (the “Purchaser”).
WARRANT TO PURCHASE ORDINARY SHARES of I-MAB Dated as of [●], 2020I-Mab • December 1st, 2020 • Pharmaceutical preparations
THIS CERTIFIES THAT, for value received, [Name of Investor], or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from I-Mab, a company incorporated under the laws of the Cayman Islands (the “Company”), ordinary shares of the Company, par value of US$0.0001 per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the subscription agreement, dated as of September 1, 2020, by and among the Company and the Holder described therein (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement. The Holder is subject to certain restrictions set forth in the T
THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED I-Mab Biopharma...Transfer and Investment Agreement • December 1st, 2020 • I-Mab • Pharmaceutical preparations
This EQUITY TRANSFER AND INVESTMENT AGREEMENT (this “Agreement”) is entered into in the PRC on Sep 15, 2020 (the “Signing Date”) by and among the following parties:
THE SYMBOL “[Redacted]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND...License and Collaboration Agreement • December 1st, 2020 • I-Mab • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made and entered into as of September 3, 2020 (the “Execution Date”) by and between I-Mab Biopharma Co., Ltd. (“I-Mab Shanghai”, 天境生物科技(上海)有限公司) and I-Mab Biopharma US Limited (“I-Mab US” and collectively with I-Mab Shanghai, “I-Mab”), and AbbVie Ireland Unlimited Company, an Irish private unlimited company (“AbbVie”). I-Mab and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED I-Mab Biopharma...Shareholders Agreement • December 1st, 2020 • I-Mab • Pharmaceutical preparations
This SHAREHOLDERS AGREEMENT (this “Agreement”) is entered into in the PRC on September 15, 2020 (the “Signing Date”) by and among the following parties:
